Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Recurrence 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1HER2-positive Breast Cancer 1Gastroesophageal Junction Cancer 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Non-small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1Advanced Malignant Neoplasm 1Advanced Esophageal Carcinoma 1Advanced Breast Cancer 1

Interventions

Injections 2Fulvestrant 2trastuzumab deruxtecan 1toripalimab 1palbociclib 1dalpiciclib 1Sirolimus 1Paclitaxel 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Breast Cancer × Docetaxel × Clear all
NCT07083505 2025-07-24

A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡